Integrin Activation to Augment SARS-CoV-2 Vaccination

Document text

Principal Investigator: JEFFREY K ACTOR
Organization: 7 HILLS PHARMA, LLC
Fiscal Year: 2021
Award: $297,724
Funding agency: National Institute of Allergy and Infectious Diseases

Abstract
On March 11, 2020 the World Health Organization (WHO) announced a global Coronavirus
Disease 2019 (COVID-19) pandemic. The disease is characterized by severe flu-like symptoms,
with advanced age (>65 years) an important risk factor for SARS-CoV-2-induced death. Current
clinical stage CoV-2 vaccine programs must include this important and vulnerable population in
their initial testing, and generate rapid antibody and cellular specific responses to combat
disease. Integrin activating compounds are immune modulators that can potentiate productive
responses to vaccine antigens; our preliminary data gives us strong confidence they may be
similarly effective in enhancing effectiveness of a coronavirus (COVID-19) vaccine, especially in
aged populations. This study will directly test the hypothesis that a novel, proprietary integrin
activator (7HP349) delivered with the SARS-CoV-2 spike protein (RBD containing domain)
vaccine candidate will generate high titer neutralizing antibodies that will yield protective
outcome (neutralization) post challenge with viral agents. Our premise is that 7HP349 can be
used as oral immune activator to augment systemic immunity of vaccines as a prophylactic tool
to control spread of SARS-CoV-2. It is furthermore envisioned to be used with an existing
vaccine without requiring antigen reformulation. Our ultimate goal is to ameliorate coronavirus
burden and subsequent COVID-19 disease in both adult and aged individuals.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><21+ years old><65+ years old><Ab response><Adjuvant><Adult><Adult Human><Aged 65 and Over><Animals><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Antibody titer measurement><Antigens><Antiviral Agents><Antiviral Drugs><Antivirals><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 S protein><COVID-19 associated death><COVID-19 associated fatality><COVID-19 associated mortality><COVID-19 crisis><COVID-19 death><COVID-19 epidemic><COVID-19 fatality><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced death><COVID-19 induced fatality><COVID-19 induced mortality><COVID-19 infection><COVID-19 mortality><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 related death><COVID-19 related fatality><COVID-19 related mortality><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 S protein><COVID19 associated death><COVID19 associated fatality><COVID19 associated mortality><COVID19 crisis><COVID19 death><COVID19 epidemic><COVID19 fatality><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 induced death><COVID19 induced fatality><COVID19 induced mortality><COVID19 infection><COVID19 mortality><COVID19 pandemic><COVID19 public health crisis><COVID19 related death><COVID19 related fatality><COVID19 related mortality><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccination><COVID19 vaccine><COVID19 virus><CV-19><CV19><Clinical><Clinical Research><Clinical Study><Clinical Trials><CoV-2><CoV2><Coronaviridae><Coronavirus><Data><Disease><Disorder><Dose><Effectiveness><Elderly><Evaluation><Fluzone><Generations><Goals><Health><Health Benefit><Histologic><Histologically><Host Defense><Human><IMiD><Immune><Immune modulatory therapeutic><Immune response><Immunes><Immunity><Immunization><Immunize><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunomodulators><Immunostimulation><Individual><Integrins><Integrins Extracellular Matrix><Knowledge><Lead><Lung diseases><Medicine><Metabolic Diseases><Metabolic Disorder><Mice><Mice Mammals><Modeling><Modern Man><Morbidity><Morbidity - disease rate><Murine><Mus><New York><Oral><Outcome><Pathogenicity><Patients><Pb element><Phase><Phase I Study><Pneumonia><Population><Preparation><Public Health><Pulmonary Diseases><Pulmonary Disorder><Recombinant Proteins><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><Risk Factors><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 associated death><SARS-CoV-2 associated fatality><SARS-CoV-2 associated mortality><SARS-CoV-2 death><SARS-CoV-2 epidemic><SARS-CoV-2 fatality><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced death><SARS-CoV-2 induced fatality><SARS-CoV-2 induced mortality><SARS-CoV-2 infection><SARS-CoV-2 mortality><SARS-CoV-2 pandemic><SARS-CoV-2 related death><SARS-CoV-2 related fatality><SARS-CoV-2 related mortality><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Schedule><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Symptoms><T cell response><Testing><Thesaurismosis><Transmission><Vaccinated><Vaccination><Vaccine Antigen><Vaccines><Viral><Virus><Vulnerable Populations><World Health Organization><Wuhan coronavirus><adulthood><advanced age><age 65 and greater><age 65 and older><aged><aged 65 and greater><aged population><aged ≥65><aging population><anti-viral agents><anti-viral drugs><anti-virals><antibody biosynthesis><antibody titering><base><co-morbid><co-morbidity><college><collegiate><combat><comorbidity><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 associated death><coronavirus disease 2019 associated fatality><coronavirus disease 2019 associated mortality><coronavirus disease 2019 crisis><coronavirus disease 2019 death><coronavirus disease 2019 epidemic><coronavirus disease 2019 fatality><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced death><coronavirus disease 2019 induced fatality><coronavirus disease 2019 induced mortality><coronavirus disease 2019 infection><coronavirus disease 2019 mortality><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related death><coronavirus disease 2019 related fatality><coronavirus disease 2019 related mortality><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><death due to COVID-19><death due to COVID19><death due to SARS-CoV-2><death due to coronavirus disease 2019><death due to severe acute respiratory syndrome coronavirus 2><death in COVID><death in COVID-19><death in SARS-CoV-2><death in coronavirus disease><death in coronavirus disease 2019><death in severe acute respiratory syndrome coronavirus 2><disease of the lung><disorder of the lung><dosage><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><elders><evaluate efficacy><examine efficacy><experiment><experimental research><experimental study><fatality due to COVID-19><fatality due to COVID19><fatality due to SARS-CoV-2><fatality due to coronavirus disease 2019><fatality due to severe acute respiratory syndrome coronavirus 2><flu><geriatric><hCoV19><heavy metal Pb><heavy metal lead><host response><human old age (65+)><human subject><immune modulating agents><immune modulating drug><immune modulating therapeutics><immune modulators><immune modulatory agents><immune modulatory drugs><immune system response><immunogen><immunogenicity><immunoglobulin biosynthesis><immunomodulating agents><immunomodulatory agents><immunomodulatory drugs><immunomodulatory therapeutics><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infectious disease model><late life><later life><lung disorder><medical college><medical schools><meetings><metabolism disorder><mortality><mortality due to COVID-19><mortality due to COVID19><mortality due to SARS-CoV-2><mortality due to coronavirus disease 2019><mortality due to severe acute respiratory syndrome coronavirus 2><nCoV2><neutralizing antibody><novel><old age><older adult><older person><phase 1 study><phase 2 study><phase II study><population aging><programs><prophylactic><receptor binding><receptor bound><response><safety study><school of medicine><senior citizen><seroconversion><severe acute respiratory syndrome coronavirus 2 associated death><severe acute respiratory syndrome coronavirus 2 associated fatality><severe acute respiratory syndrome coronavirus 2 associated mortality><severe acute respiratory syndrome coronavirus 2 death><severe acute respiratory syndrome coronavirus 2 fatality><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced death><severe acute respiratory syndrome coronavirus 2 induced fatality><severe acute respiratory syndrome coronavirus 2 induced mortality><severe acute respiratory syndrome coronavirus 2 mortality><severe acute respiratory syndrome coronavirus 2 related death><severe acute respiratory syndrome coronavirus 2 related fatality><severe acute respiratory syndrome coronavirus 2 related mortality><tool><transmission process><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine effectiveness><vaccine for novel coronavirus><vulnerable group>